Navigation Links
Monogram Announces Conference Call
Date:10/23/2008

LEADING HIV PHYSICIAN, Dr. DAVID HARDY, TO DISCUSS CLINICAL USE OF THE TROFILE(TM) ASSAY AND SELZENTRY(TM) IN CONJUNCTION WITH THE THIRD QUARTER

2008 FINANCIAL RESULTS CONFERENCE CALL

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's CCR5 antagonist, Selzentry(TM). Monogram will also review its third quarter 2008 financial results. The call will be hosted by William D. Young, Chairman & CEO of Monogram. Dr. David Hardy will participate in the call. Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and is Associate Professor of Medicine-in-Residence at the David Geffen School of Medicine at UCLA.

To participate in the live teleconference, please call (877) 604-9672, or (719) 325-4896 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available on the Investor Relations section at http://www.monogrambio.com. Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through Sunday, November 9, 2008. The replay passcode is 4461917. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a trademark of Pfizer Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Receives NASDAQ Notification
2. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
5. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
7. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
8. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
11. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 ... Efforts by Enabling Scientific Understanding of Complex Diseases ... Rare Diseases --> ... diagnostics in South Asia and a leading provider of ... contribute $10 million to the GenomeAsia 100K consortium ...
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... than 150 years, continues today to pursue the highest level of accuracy and ... instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and tough ...
Breaking Biology Technology:
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
Breaking Biology News(10 mins):